SCHEMBL6236560

SCHEMBL6236560

CC(=O)c1cc(C(=O)O)ccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 7/20 0.74
KDM5C P41229 6/20 0.74
KDM4C Q9H3R0 5/20 0.74
KDM4A O75164 5/20 0.74
KDM5B Q9UGL1 5/20 0.74
ALKBH5 Q6P6C2 4/20 0.74
KDM6B O15054 4/20 0.74
KDM2A Q9Y2K7 4/20 0.74
KDM3A Q9Y4C1 4/20 0.74
KDM4E B2RXH2 4/20 0.74
ALDH1A1 P00352 3/20 0.74
KDM5A P29375 2/20 0.74
TET3 O43151 1/20 0.74
BBOX1 O75936 1/20 0.74
MAPT P10636 1/20 0.74
ASPH Q12797 1/20 0.74
KDM4D Q6B0I6 1/20 0.74
TET2 Q6N021 1/20 0.74
KDM7A Q6ZMT4 1/20 0.74
KDM8 Q8N371 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13165469 0.88 ALDH1A1 (0.55) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL29382783 0.85 KDM5C (1.00) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL72377 0.85 KDM5C (1.00) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL20915176 0.85 FTO (0.69) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL9966085 0.84 KDM4E (0.74) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL31368524 0.84 KDM4E (0.74) FTOKDM5CKDM4CKDM4AKDM5B
Water SCHEMBL2650345 0.83 KDM5C (0.96) FTOKDM5CKDM4CKDM4AKDM5B
Hydrochloric Acid SCHEMBL9361001 0.83 KDM5C (0.96) FTOKDM5CKDM4CKDM4AKDM5B
Hydrochloric Acid SCHEMBL10778857 0.83 KDM5C (0.96) FTOKDM5CKDM4CKDM4AKDM5B
SCHEMBL9585979 0.83 FTO (0.96) FTOKDM5CKDM4CKDM4AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
CN-116710430-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2023-09-05 CN disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed
CN-113264945-B Spiro derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 WO disclosed
CN-113264945-A Spiro derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2021-08-17 CN disclosed
WO-2017198785-A1 OXIME DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASE KDM4C IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-11-23 WO disclosed
US-5808124-A BINDING TO RETINOID RECEPTORS ALLERGAN (US) 1998-09-15 US disclosed
EP-0853610-A2 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES Allergan (US) 1998-07-22 EP disclosed
US-5776699-A MEASURING GENE EXPRESSION ALLERGAN, INC. (US) 1998-07-07 US disclosed
US-5773594-A TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF OTHER RETINOIDS ALLERGAN (US) 1998-06-30 US disclosed
US-5763635-A Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity ALLERGAN (US) 1998-06-09 US disclosed
US-5747542-A SKIN DISORDERS; ANTICANCER AGENTS ALLERGAN (US) 1998-05-05 US disclosed
US-5741896-A O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity ALLERGAN (US) 1998-04-21 US disclosed
US-5723666-A USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION ALLERGAN (US) 1998-03-03 US disclosed
WO-1997048672-A2 SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY ALLERGAN SALES, INC. (US) 1997-12-24 WO disclosed
WO-1997009297-A2 SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES VISION PHARMACEUTICALS L.P. (US) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS FTO 4685/4885KDM5C 3061/4885KDM4C 2895/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS FTO 4685/4885KDM5C 3061/4885KDM4C 2895/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS FTO 4685/4885KDM5C 3061/4885KDM4C 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.